Log In
BCIQ
Print this Print this
 

TG03

  Manage Alerts
Collapse Summary General Information
Company Targovax A/S
Description 
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationMelanoma
Indication DetailsTreat malignant melanoma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$29.8M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/02/2015

$29.8M

0

0

Get a free BioCentury trial today